Nika Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing continued operating losses, no revenue, and a total stockholders' deficit of $343,705.

Key Highlights

  • No revenue: The company reported $0 in revenue for both the three and nine months ended September 30, 2026, according to the filing.
  • Net loss of $46,077: The net loss for the nine months ended September 30, 2026 was $46,077, compared to $39,309 for the same period in 2025.
  • Total assets of $5,309: As of September 30, 2026, total assets consisted of $352 in cash and $4,957 in prepaid expenses.
  • Stockholders' deficit widened: The accumulated deficit reached $9,050,086 and total stockholders' deficit stood at $(343,705) as of September 30, 2026, versus $(297,628) at December 31, 2025.
  • Related-party financing: The company received $30,390 in loans from related parties during the nine months ended September 30, 2026, with amounts due to related parties totaling $349,014 at period end.
  • Shares outstanding: Common shares outstanding were 1,054,689,224 as of October 15, 2026, with 15,000,000 preferred shares also issued and outstanding.

Nika Pharmaceuticals Reports No Revenue and Growing Deficit Through September 2026

Nika Pharmaceuticals, Inc., a Colorado-incorporated smaller reporting company and emerging growth company, filed its unaudited condensed consolidated financial statements for the quarterly period ended September 30, 2026. The filing does not identify a trading exchange or ticker symbol on the cover page's registered-securities table. The company reported no revenue for either the three-month or nine-month periods ended September 30, 2026, and no revenue for the comparable periods in 2025.

According to the filing, total operating expenses for the nine months ended September 30, 2026 were $46,077, consisting of $25,665 in general and administrative costs and $20,412 in professional fees. For the three months ended September 30, 2026, total operating expenses were $13,023, up from $7,982 in the same quarter of 2025. The company reported no provision for income taxes and no cash paid for taxes or interest during either period covered.

The balance sheet as of September 30, 2026 showed total assets of $5,309 against total liabilities of $349,014, all of which consisted of amounts due to related parties. Cash on hand was $352, down from $1,889 at December 31, 2025. The company disclosed that during the nine-month period, 7,140,000 common shares were issued through what the filing describes as "common control merger" transactions, with no net impact on additional paid-in capital. The accumulated deficit grew from $9,004,009 at December 31, 2025 to $9,050,086 at September 30, 2026.

What Was Disclosed

Nika Pharmaceuticals disclosed its unaudited financial results for the nine months ended September 30, 2026, reporting no revenue, a net loss of $46,077, total assets of $5,309, related-party liabilities of $349,014, and a total stockholders' deficit of $343,705.